Cal-X Stars. Innovation and Business Accelerator FOCUSED on Launching Great Cardiovascular and Social Good Impact Companies. Super brief history.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Innovation and Business Accelerator
FOCUSED on Launching Great Cardiovascular and Social Good Impact Companies
Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc.Presenter: Howard J. Leonhardt, Founder, CEO1531 6th Street, Unit 401, Santa Monica, CA 90401Office Direct 310 310 2534
Heart Failure = Leading economic drain on U.S. healthcare system. 50 million about to die in next 3-5 years worldwide without a better solution. No current therapy addresses underlying problem of recovering heart scar tissue post heart attack.
Social good impact financing = NYSE, NASDAQ, VCs, Formal Angel Groups all fail to meet the financing needs of life science and other social good impact cos. years 3 to 9. It takes 9 years for a good co these days to get to a NASDAQ IPO up from 3 in the early 1980’s. Most life science and other social good startups run out of seed financing by about year 3. VCs and angel groups increasingly want to see revenues before investing. The FDA approval process has lengthened to more than 5 years to get approval for any major new breakthrough technology.
Heart Failure = We are the only ones that have developed and patented a reliable way to convert heart scar tissue into new living pumping muscle which allows heart failure patients to recover.
We are leaders in muscle stem cells, SDF-1, electrical stimulation, nutrient hydrogel, implantable stem cell pumps, wireless energy for growth factor release and stem cell recruitment and differentiation, perfusion improving heart pumps. We are the only ones with the complete solution. We pre-treat the scar, treat the scar with stem cell transplantation creating new contractile muscle and post treat the area to maintain and build on original muscle growth. No one else comes close to a complete solution. Where others are tapping out at 53 meters improvement in a patient’s exercise capacity we are expecting over 200 meters improvement, or better.
We have built an all star team of over 40 proven industry veterans with over $14 billion in exits in the cardiovascular space alone. Our scientific advisory board, research and clinical investigation teams includes over 70 world leaders in the space. Our cGMP manufacturing team has over 30 years experience.
Howard J. Leonhardt, Chairman & CEO – 21 U.S. patents. Has brought more than five cardio products to market leadership positions. Over 200,000 patients have been treated with Leonhardt inventions to date. His TALENT thoracic stent graft captured 70% world market share before being sold to Medtronic.
Alex Richardson – CEO Core Manufacturing – 30 years experience in electronics and medical device cos primarily with Alfed Mann companies.
Jeremy Koff – VP Business Development – 20+ years in product launch experience primarily with Alfred Mann companies.
Alan Remen – 30 years operational management experience in technology companies.
Dr. William Abraham – Chairman Scientific Advisory Board – Chief of Heart Failure at OSU. PI of the MIRACLE trial that launched the $9 billion CRT/ICD era of heart failure treatment.
Above table is in 000’s.
Cardio Total Invested $8,400,000
Total Projected Best Case Optimistic Return = $194,550,000 Year 5
Social Impact Total Invested $3,900,000
Total Projected Best Case Optimistic Return = $33,672,032 Year 5
Note – These are breakthrough first ever products un-tested in markets. Markets are big – really big. This is very very difficult to predict. We are focused on addressing great market needs with far superior products.